Loading...
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Entrectinib is a potent small-molecule tyrosine kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1, and ALK. The consolidated results of 2 Phase I trials demonstrated activity in tyrosine kinase inhibitor-naïve patients along with substantial intracranial activity. In ROS1-rearrang...
Na minha lista:
| Udgivet i: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055893/ https://ncbi.nlm.nih.gov/pubmed/30050303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S147381 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|